Why Has Janney Capital Given Cempra Inc (NASDAQ:CEMP) a $43.00 Price Target
Janney Capital analyst have begun coverage with a “Buy” rating on Cempra Inc (NASDAQ:CEMP) today and set a price target of $43.00. The firm’s shares opened today at 29.56.
From a total of 11 analysts covering Cempra (NASDAQ:CEMP) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 1 a ”Hold”. This means that 92% of the ratings are positive. The highest target price is $51 while the lowest target price is $21. The mean of all analyst targets is $41.27 with a 44.35% above today’s ($29.56) stock price. Cempra was the topic of 8 analyst reports since July 30, 2015 according to the firm StockzIntelligence Inc. Morgan Stanley upgraded shares on November 16 to “Overweight” rating. TH Capital maintained CEMP stock in a recent report from October 19 with “Buy” rating. Finally, Needham maintained the stock with “Buy” rating in a report issued on a July 30.
Approximately 586,326 shares of stock traded hands. Cempra Inc (NASDAQ:CEMP) has declined 8.76% since May 8, 2015 and is downtrending. It has underperformed by 5.74% the S&P500.
The overall sentiment of institutions has decreased to 1.14 in Q2 2015. Its down 0.71, from 1.85 in 2015Q2. The ratio fall, as 31 institutions have sold all the shares of Cempra Inc that they owned while 45 funds have taken shares off the table. 28 funds have purchased shares for the first time while 59 added to their positions. These institutions now hold 38.41 million shares or 40.72% more than the 27.30 million shares they owned in 2015Q2.
The Fund Aisling Capital Llc currently is holding shares equating to 10.73% of its total portfolio in Cempra Inc representing a total of 2.19 million shares. Another fund,Abingworth Llp, is holding a total of 383,935 shares equating to 6.24% of their holdings. Additionally, Opaleye Management Inc. has a 360,000 share stake in Cempra Inc which represents 4.93% of their total portfolio. The Fund, Harvey Capital Management Inc, based out of Florida, has also built up a stake in the stock, which represents a total of 2.49% of their total portfolio. Finally Alpinvest Partners B.V., a fund which is based in the state of Netherlands reported a total holdings of 40,000 shares.
Insider activity is a very important aspect to track on any stock. Going back to May 27, 2015, shareholders of Cempra Inc have witnessed 2 insider purchases, and a total of 1 insider sale equating to a net activity of approximately $1.70 million . Dougherty Michael R bought 2,000 shares worth approximately $36,896. Kong Garheng bought 2,830 shares worth approximately $49,335. Goldstein Dov A Md sold 50,000 shares worth approximately $1.79M. Fernandes Prabhavathi sold 9,000 shares worth approximately $321,489.
Cempra Inc. is a clinical-stage pharmaceutical firm focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The company has a market cap of $1.36 billion. The Company’s lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. It currently has negative earnings. The Company’s second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States.
According to Zacks Investment Research, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina.” Get a free copy of the Zacks research report on Cempra Inc (CEMP).